Aarti Drugs reports comprehensive income of ₹17,169 crore for FY26

Arunika Jain — Fri, 15 May 2026 13:23:12 +0000

Aarti Drugs Limited has announced its audited standalone and consolidated financial results for the quarter and year ended 31 March 2026. The company’s total comprehensive income for the year stood at ₹17,169 crore, reflecting a robust financial performance.

The board of directors approved the financial results during a meeting held on 15 May 2026. The meeting commenced at 2:50 PM and concluded at 4:40 PM. The results include statements of assets and liabilities, cash flow statements, and auditor’s reports, all of which were presented with unmodified opinions.

In addition to the financial results, the board approved the re-appointment of M/s GMVP & Associates LLP as the cost auditor for the financial year ending 31 March 2027. The firm, based in Mumbai, has been in the field of costing, finance, and accounts for 35 years.

Furthermore, M/s Raman S. Shah & Co. has been re-appointed as the internal auditor for three consecutive financial years starting from 1 April 2026. The firm is known for its extensive experience in internal and statutory audit services, GST compliances, and tax audit services.

The board also reconstituted its Risk Management Committee, adding Shri Narendra J. Salvi, a non-executive, non-independent director, as a member. The committee now includes key figures such as Shri Prakash M. Patil, Shri Rashesh C. Gogri, and Shri Harshit M. Savla, among others.

Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).

Rashesh C. Gogri | Business Upturn

Aarti Drugs reports comprehensive income of ₹17,169 crore for FY26